Cullinan Therapeutics Inc.

This early-stage study tests a new drug called CLN-978 in 24 people with moderate to severe systemic lupus erythematosus (SLE). The goal is to see if the drug is safe and how it affects the body, including reducing immune cells linked to the disease. Participants receive the drug…

This early-phase study tests a new drug called CLN-049 in about 60 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. CLN-049 is designed to help the body's immune cells attack cancer cells. The main goals …

This early-stage study tests a new drug, CLN-978, in 37 adults with rheumatoid arthritis that hasn't responded to other treatments. The goal is to see if the drug is safe and can control the disease by lowering certain immune cells. Participants must have active arthritis and sig…

This early-stage study tests a new drug, CLN-978, in 36 adults with active, moderate to severe Sjogren's disease. The main goal is to check safety and side effects. Researchers will also measure how the drug affects immune cells and stays in the body. Participants receive the dru…